Cosmos Holdings Submits Application for NASDAQ Capital Market Up-Listing
CHICAGO, June 25, 2018 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB:COSM), an international pharmaceutical company, has submitted its formal application to list the company's common stock on the NASDAQ Capital Market.
Cosmos Holdings CEO Gregory Siokas commented, "We believe up-listing to NASDAQ will increase awareness of Cosmos Holdings in the financial community. This process to up-list to NASDAQ reflects the significant progress we have made in strengthening our corporate governance, improving operating efficiencies, and positioning the company for growth and profitability. In addition to improving trading liquidity for our shareholders, we expect this listing to provide greater awareness of our unique approach in the international pharmaceutical market, and enable us to attract a broader audience in the investment community.”
Acceptance for listing Company shares is subject to approval, in part, based on the Company's ability to meet minimum NASDAQ listing requirements. While the Company intends to satisfy all of NASDAQ's listing criteria, no assurance can be given that its application will be approved. During the NASDAQ review process, the Company's common stock will continue to trade on the OTCQB under its current symbol, COSM.
About the NASDAQ
The NASDAQ is global electronic marketplace for buying and selling securities. It was created by the National Association of Securities Dealers (NASD) to enable investors to trade securities on a computerized, speedy and transparent system. For more about the NASDAQ, go to www.nasdaq.com.
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. is a pharmaceutical wholesaler with offices and warehouses in Thessaloniki, Greece and in Harlow, UK. The Company has a trans-European network of over 110 clients and vendors which expands to 16 countries including: Germany, United Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, Netherlands, and Greece. More information is available at www.cosmosholdingsinc.com.
FORWARD LOOKING STATEMENTS
Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.
Investor Relations Contact
Andrew Barwicki
Tel: 516-662-9461
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
